NCT01711554 2026-03-18
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT04446962 2025-09-25
LOC-R01
Institut Curie
Phase 1/2 Active not recruiting
NCT01553149 2025-01-07
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT04049864 2022-03-02
DNA Vaccination Against Neuroblastoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase EARLY_PHASE1 Unknown
NCT01222754 2022-01-03
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03050450 2021-04-05
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Johns Hopkins All Children's Hospital
Phase 1 Terminated
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00036894 2015-04-30
CC-5013 in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00100880 2013-09-30
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00165477 2010-03-10
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed